StockNews.com initiated coverage on shares of Jaguar Health (NASDAQ:JAGX - Free Report) in a research note released on Friday morning. The brokerage issued a sell rating on the biotechnology company's stock.
Jaguar Health Stock Down 4.8 %
JAGX traded down $0.24 during trading hours on Friday, reaching $4.76. The company's stock had a trading volume of 23,464 shares, compared to its average volume of 27,949. The business's 50-day moving average is $16.18 and its 200-day moving average is $23.03. The company has a current ratio of 1.84, a quick ratio of 1.36 and a debt-to-equity ratio of 1.65. Jaguar Health has a fifty-two week low of $4.61 and a fifty-two week high of $540.00.
Institutional Trading of Jaguar Health
A hedge fund recently bought a new stake in Jaguar Health stock. Virtu Financial LLC bought a new position in shares of Jaguar Health, Inc. (NASDAQ:JAGX - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 25,591 shares of the biotechnology company's stock, valued at approximately $35,000. Virtu Financial LLC owned 0.22% of Jaguar Health at the end of the most recent reporting period. 12.04% of the stock is currently owned by hedge funds and other institutional investors.
About Jaguar Health
(
Get Free Report)
Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.
Further Reading
Before you consider Jaguar Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jaguar Health wasn't on the list.
While Jaguar Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
